Abdulafeez Akinloye
Higher Degree by Research Candidate
School of Pharmacy and Biomedical Sciences
College of Health
Abdulafeez Akinloye is PhD Student in the Mass Sepctrometry and Proteomics Group under the supervision of Professor Peter Hoffmann. His interests lie in the application of mass spectrometry and spectroscopic methods for the analysis of both small and large drug molecules (such as protein therapeutics) to support initial drug discovery and development, formulation process as well as pharmacokinetic applications. His PhD project, in collaboration with CSL Ltd, focuses on the investigation of monoclonal antibody degradation products with middle-down and top-down MS using an electron-based fragmentation method. Originally from Nigeria, he obtained a Bachelor of Pharmacy and an MSc in Pharmaceutical Chemistry from Obafemi Awolowo University (OAU) in 2015 and 2021 respectively. His previous role as a Research Assistant in the Translational Pharmacokinetic Research Group (TPRG) in OAU, involved the development of bioanalytical methods for drug quantification in formulations and various biological fluids (such as plasma, dried blood spot and saliva), and the applications to pharmacokinetic analysis for safety, efficacy, and pharmacogenetic purposes.
| Date | Institution name | Country | Title |
|---|---|---|---|
| 2018 - 2021 | Obafemi Awolowo University | Nigeria | MSc in Pharmaceutical Chemistry |
| 2009 - 2015 | Obafemi Awolowo University | Nigeria | Bachelor of Pharmacy |
| Year | Citation |
|---|---|
| 2025 | Adeagbo, B. A., Alao, M., Orherhe, O., Akinloye, A., Boukes, G., Willenburg, E., . . . Fox, C. B. (2025). Lyophilization Strategy Enhances the Thermostability and Field-Based Stability of Conjugated and Comixed Subunit Liposomal Adjuvant-containing Tuberculosis Vaccine Formulation (ID93 + GLA-LSQ). Molecular Pharmaceutics, 22(4), 2306-2315. |
| 2024 | Eniayewu, O., Akinloye, A., Shenkoya, B., Azuka, U., Bolaji, O., Adejuyigbe, E., . . . Olagunju, A. (2024). Prenatal efavirenz exposure is independently associated with maternal, but not fetal CYP2B6 genotype. Pharmacogenetics and Genomics, 34(8), 253-260. |
| 2024 | Akinloye, A., Oyedeji, T., Eniayewu, O., Adeagbo, B., Bolaji, O., Rannard, S., . . . Olagunju, A. (2024). Atazanavir/Ritonavir Increased Tizoxanide Exposure from Oral Nitazoxanide through Pharmacokinetic Interaction in Healthy Volunteers. FUTURE PHARMACOLOGY, 4(1), 163-172. |
| 2022 | Fowotade, A., Bamidele, F., Egbetola, B., Fagbamigbe, A. F., Adeagbo, B. A., Adefuye, B. O., . . . Olagunju, A. (2022). A randomized, open-label trial of combined nitazoxanide and atazanavir/ritonavir for mild to moderate COVID-19. FRONTIERS IN MEDICINE, 9, 12 pages. WoS5 Europe PMC3 |
| 2022 | Akinloye, A., Eniayewu, O., Adeagbo, B., Bolaji, O., & Olagunju, A. (2022). Validation and Clinical Application of a Liquid Chromatography-Ultraviolet Detection Method to Quantify Dolutegravir in Dried Blood Spots. THERAPEUTIC DRUG MONITORING, 44(3), 430-437. WoS4 Europe PMC2 |
| 2021 | Shenkoya, B., Atoyebi, S., Eniayewu, I., Akinloye, A., & Olagunju, A. (2021). Mechanistic Modeling of Maternal Lymphoid and Fetal Plasma Antiretroviral Exposure During the Third Trimester. FRONTIERS IN PEDIATRICS, 9, 11 pages. WoS9 Europe PMC8 |
Connect With Me
External Profiles
